CTIS2024-513971-42-00进行中（未招募）1 期
A Randomized Clinical Trial, Multicentre, Open-label, Parallel-group, to define the best Strategy for the management of hEart failure aNd chronic kidney disease among elderly patients with or at high risk of hyperKalemia in spAin by optimizing the use of RAASi with SZC: SENEKA Study - SENEKA
Hospital Clinico Universitario De Valencia0 个研究点目标入组 94 人开始时间: 2024年5月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65 至 65+（—）
- 性别
- All
入选标准
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol., Hyperkalemic patients (sK+ 5.1–5.9 mmol/L at screening / study enrolment) or Normokalemic, Provision of informed consent form prior to any study specific procedures, sampling and analysis., Individuals must be = 70 years of age at the time of signing the informed consent form., Individuals must have a confirmed diagnosis of Heart Failure (HF) according to clinical practice guidelines NYHA functional class I-III (with HFrEF or HFpEF)., Individuals must have previously been admitted to hospital due to HF decompensation requiring intravenous diuretics., Individuals must have been stabilised for at least 24-48h of their HF decompensation before randomisation., Individuals must have a confirmed diagnosis of Chronic Kidney Disease defined as a renal impairment of eGFR less than 60ml/min/1.73 m2., Individuals receiving background standard of care for HF and treated according to international guidelines. Specific treatment should include RAASi and/or MRA treatment and at least should have been stable for = 4 weeks at maximum tolerated doses., Patients on RAASi blocker treatment with less than or equal to 75% of the maximum recommended dose.
排除标准
- •Limited life expectancy (less than 1 year) according to clinician’s criteria, such as but not limited to malignancy, with life expectancy of less than 2 years based on investigator’s clinical judgement., Congenital long QT syndrome., Prior history of hypersensitivity to a RAAS blocker drug, including but not limited to development of angioedema, icterus, hepatitis, or neutropenia or thrombocytopenia requiring treatment modification. Addison’s disease or other causes of hypoaldosteronism., Patients with a known hypersensitivity to SZC or any of the excipients of the product., Individuals treated with potassium binding resins such as sodium polystyrene sulfonate (SPS, e.g. Kayexalate®) or calcium polystyrene sulfonate (CPS; e.g. Resonium®) or the cation exchange polymer, patiromer sorbitex calcium (Veltassa®) within 7 days prior to the first dose of study drug., Treated with potassium supplements within 7 days prior to randomization., Positive hepatitis C antibody hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening., Known to have tested positive for human immunodeficiency virus., Known history of drug or alcohol abuse within 3 year of screening., Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)., Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements., sK >6 mEq/litre or <4.5mEq/litre or history of hypokalemic episodes (S-K<3.5 mEq/L) during the last year., Previous enrolment in the present study., Participation in another clinical study with an investigational product during the last 3 months., Patients on haemodialysis or haemofiltration, NYHA functional class IV, Patients undergoing treatment with potassium binders., Active tumour undergoing chemotherapy or metastasis or malignancy requiring treatment., Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted., QTc(f) > 550 msec., History of QT prolongation associated with other medications that required discontinuation of that medication.
研究者
相似试验
招募中
4 期
A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)ovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003004nion Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
已完成
不适用
Evaluate the efficacy and safety of MINTLIFT Group for Nasolabial FoldKCT0001098Hans Biomed Corporation62
进行中（未招募）
不适用
Previous Study | Return to List | Next Study A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA) (SAIZEN in SGA)Small for Gestational AgeEUCTR2015-001681-25-Outside-EU/EEAMerck KGaA25
进行中（未招募）
1 期
Study to compare Buckberg cardioplegia and Del Nido cardioplegia in isolated aortic valve replacement surgeryMyocardial protectionEUCTR2018-002701-59-ESInstitut de Recerca Hospital de la Santa Creu i Sant Pau388
已完成
不适用
A multicenter,randomized,controlled clinical trial of early vitrectomy for diffuse diabetic macular edema.diffuse diabetic macular edemaJPRN-UMIN000008957Kagoshima University Graduate School of Medical and Dental Science162